Tirzepatide: Mechanism of Action

Mechanism of Action

Dual Incretin Receptor Agonism

Tirzepatide is a full agonist at both the GIP receptor and the GLP-1 receptor - class B (secretin-family) Gs-coupled GPCRs expressed on pancreatic beta-cells and alpha-cells, adipocytes, and central-nervous-system neurons involved in appetite regulation. Receptor occupancy elevates intracellular cAMP and activates PKA signaling, which in the beta-cell potentiates glucose-dependent insulin secretion.[4][2]

Imbalanced / Biased Agonism

Pharmacology studies describe tirzepatide as an imbalanced dual agonist: it behaves much like native GIP at the GIP receptor, but shows biased agonism at the GLP-1 receptor, with comparatively weaker beta-arrestin recruitment relative to cAMP signaling. This distinctive signaling profile is an active area of research into how co-agonism differs mechanistically from single GLP-1-receptor agonism.[4]

DPP-IV Resistance and Pharmacokinetics

The two Aib substitutions eliminate the N-terminal DPP-IV cleavage sites, and the C20 fatty-diacid moiety drives reversible albumin binding. Together these modifications extend the circulating half-life to about five days, enabling sustained dual-receptor activation in once-weekly research dosing models.[1]

Metabolic Endpoints in Research Models

Endpoint	Direction	Model Context
Glucose-dependent insulin secretion	Increased	Isolated islet and rodent glucose-tolerance models[1]
Glucagon (fasting)	Modulated	Clamp and mixed-meal research protocols[2]
Gastric emptying	Slowed	Acetaminophen-absorption and imaging models[2]
Food intake / body weight	Decreased	Diet-induced-obese rodent models[7]
Adipose insulin sensitivity	Increased	Metabolic-phenotyping research models[7]

Receptor Selectivity

Tirzepatide engages the GIP and GLP-1 receptors with high potency and does not significantly activate the glucagon receptor, distinguishing it from triple-agonist peptides such as retatrutide.[6]